Details of the Drug Combination

General Information of Drug Combination (ID: DCGSCH2)

Drug Combination Name
INCB039110 INCB24360
Indication
Disease Entry Status REF
Solid Tumors Phase 1 [1]
Component Drugs INCB039110   DMD9RV3 INCB24360   DMIJGT9
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of INCB039110
Disease Entry ICD 11 Status REF
Malignant neoplasm 2A00-2F9Z Phase 2 [2]
Non-small-cell lung cancer 2C25.Y Phase 2 [3]
INCB039110 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [7]
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Indication(s) of INCB24360
Disease Entry ICD 11 Status REF
Urothelial carcinoma 2C92.0 Phase 3 [4]
Melanoma 2C30 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
B-cell lymphoma 2A86 Phase 1 [3]
Colorectal cancer 2B91.Z Phase 1 [3]
Head and neck cancer 2D42 Phase 1 [3]
Lung cancer 2C25.0 Phase 1 [3]
Lymphoma 2A80-2A86 Phase 1 [3]
Merkel cell carcinoma 2C34 Phase 1 [3]
Ovarian cancer 2C73 Phase 1 [3]
Recurrent glioblastoma 2A00.00 Phase 1 [6]
INCB24360 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
INCB24360 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Indoleamine 2,3-dioxygenase 1 (IDO1) OT91DBN7 I23O1_HUMAN Decreases Activity [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02559492) Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8364).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT03361865) Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307). U.S. National Institutes of Health.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8221).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
9 Incyte. Product Development Pipeline.
10 Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells. Toxicol Appl Pharmacol. 2020 Oct 1;404:115203. doi: 10.1016/j.taap.2020.115203. Epub 2020 Aug 19.